Kurze Zusammenfassung:
Roche and Genentech have shared an internal update regarding a new U.S. Executive Order focused on drug pricing. The order, titled “Delivering Most Favored Nation Prescription Drug Pricing to American Patients,” aims to benchmark U.S. drug prices against the lowest prices found in other developed countries. While still in early stages and requiring a regulatory process to implement, this policy could have major implications for the pharmaceutical industry.
The Executive Order directs the government to publish a target price list within 30 days and asks drug manufacturers to make progress toward those prices. If not, further actions — such as importing cheaper drugs — could follow. Diagnostics and medical devices are not affected.
Roche expresses concern that the policy may harm innovation, reduce R&D investment, and fail to address the root issues of high patient costs in the U.S., which often stem from intermediaries in the healthcare system. The company supports reforms that improve patient affordability without undermining scientific progress and is working with policymakers to shape more effective solutions.
No immediate impact on Roche’s business is expected this year and the company remains committed to both innovation and patient access.